Close Menu

NEW YORK – Antibody analysis firm Serimmune said on Friday that it has entered an agreement with biotech company Atreca around development of therapeutic antibodies for cancer.

Under the agreement, Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.

The SERA platform uses a combination of bacterial display peptide libraries, next-generation sequencing, and machine learning to identify antigens involved in antibody response.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.

A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.

The Los Angeles Times reports that only a third of California students meet the state's new science standards.

In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.